Physician profile
Henry Redel
NPI 1750608642
$1,474.51
in general payments reported to CMS, 2019-2025
11 companies · $403 in 2025
The $403 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.12 · 2020: $221 · 2021: $13.76 · 2022: $300 · 2023: $273 · 2024: $205 · 2025: $403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $881.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $881.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $424.21 | 2019-2025 | |
| Organogenesis INC. | $284.83 | 2022-2024 | |
| Melinta Therapeutics, LLC | $179.12 | 2022-2025 | Rezzayo, Kimyrsa, Orbactiv |
| Shionogi INC | $163.37 | 2022-2025 | Fetroja |
| Paratek Pharmaceuticals, INC. | $116.99 | 2020 | |
| Merck Sharp & Dohme LLC | $107.71 | 2019-2025 | Pifeltro, Zerbaxa, Capvaxive |
| Insmed, INC. | $85.09 | 2024-2025 | Arikayce |
| Viiv Healthcare Company | $40.71 | 2025 | Dovato |
| Invivyd INC | $37.20 | 2025 | Pemgarda |
| Urgo Medical North America, LLC | $20.35 | 2024 | Urgok2, Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Daiichi Sankyo INC. | $14.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Redel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.